# VectorY Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vectory-therapeutics

- Industry: Biotechnology
- Headquarters: Amsterdam, Netherlands
- Website: www.vectorytx.com/
- Total disclosed funding: $175M
- Latest round: Series A (Nov 13, 2023)
- Investors on record: 7

## About

Founded in 2020 and based in Amsterdam, Netherlands, VectorY operates as a biotechnology company that focuses on therapeutic solutions. In November 2023, VectorY Therapeutics raised EUR 129 million in series A funding co-led by EQT Life Sciences and Forbion, with participation from BioGeneration Ventures, Insight Partners, MRL Ventures Fund, and SUNU Ventures.

VectorY develops gene therapy for muscular and neurodegenerative disorders. The firm develops vectorized antibodies for CNS and somatic disorders.

VectorY plans to use its seed funding to establish pre-clinical proof of concept for vectorized antibodies in target indications of ALS and Alzheimer’s, expand its team, and establish manufacturing capabilities, including the GMP facility in the Netherlands.

## Funding rounds

- Series A, Nov 13, 2023, $138M — Insight Partners, EQT Life Sciences, Forbion, BioGeneration Ventures, SUNU Ventures, MRL Ventures Fund
- Seed, Jun 15, 2021, $38M — Forbion, BioGeneration Ventures, Eli Lilly & Company

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Seed, Series A
- BioGeneration Ventures (https://capitalatlas.ai/funds/biogeneration-ventures) — Seed, Series A
- Eli Lilly & Company — Seed
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- SUNU Ventures (https://capitalatlas.ai/funds/sunu-ventures) — Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A